The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...

eosinophilic esophagitis and prurigo nodularis. Hence, Regeneron has likely earned incremental profits from Dupixent in the to-be-reported quarter. However, sales growth was affected by fewer ...

Suggested treatments for eosinophilic esophagitis include proton pump inhibitors, topical steroids, empiric food elimination diet, biologics, endoscopic dilation. HealthDay News — In a clinical ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.71. Thomas Larsen: Welcome to the Q4 and Full Year 2024 Conference Call ...

Dupixent achieved over €13 billion in sales, growing 16% in Q4, with strong performance across geographies and indications. Management also noted progress in new indications such as COPD and EoE for ...

As we expand the benefits of Dupixent to more patients, we're pleased with the continued work on new indications including EoE for children in the EU, CSU outside Japan and BP globally.